UCB S.A. (USD) UCB S.A. is a prominent biopharmaceutical company dedicated to the discovery, development, and commercialization of innovative therapies for individuals affected by neurological and immunological disorders. Its extensive portfolio of marketed products includes Cimzia, indicated for various inflammatory TNF-mediated diseases such as Crohn's disease, plaque psoriasis, psoriatic arthritis, rheumatoid arthritis, ankylosing spondylitis, and axial spondyloarthritis (both radiographic and non-radiographic forms). For epilepsy management, UCB provides Vimpat, Keppra, and Briviact, alongside Nayzilam, a specialized nasal spray for acute rescue treatment of seizure clusters. Neupro is available for patients with Parkinson's disease and restless legs syndrome, while Zyrtec and Xyzal address allergy symptoms. Additionally, the company offers Evenity to treat osteoporosis in postmenopausal women, and BIMZELX, approved for conditions like psoriasis, psoriatic arthritis, axial spondyloarthritis, and hidradenitis suppurativa. Dapirolizumab pegol is also part of its offerings for systemic lupus erythematosus. In its robust development pipeline, UCB is advancing several investigational medicines, including rozanolixizumab for myasthenia gravis, immune thrombocytopenia, and chronic inflammatory demyelinating polyneuropathy; zilucoplan for myasthenia gravis and immune-mediated necrotizing myopathy; staccato alprazolam for prolonged stereotypical seizures; Bepranemab targeting Alzheimer's disease; and UCB0599 for Parkinson's disease. Beyond its core pharmaceutical activities, UCB also provides contract manufacturing services. The company has forged strategic collaboration agreements with major industry players such as Amgen, Biogen, Roche/Genentech, Novartis, Otsuka, and doc.ai. With its headquarters in Brussels, Belgium, and established in 1925, UCB maintains a significant international presence, operating across the United States, Japan, Germany, China, Belgium, and other key European markets including France, Italy, Spain, the United Kingdom, and Ireland.

UCB S.A. (USD) Active

Allée de la Recherche, 60, Brussels, BE, 1070

Stock Price USD

Price Change

Last Dividend USD

B+

Latest Rating

UCBJF's stock peer is CMXHF (CSL Limited)

UCBJF's stock peer is DSKYF (Daiichi Sankyo Company, Limited)

UCBJF's stock peer is DSNKY (Daiichi Sankyo Company, Limited)

UCBJF's stock peer is HLNCF (Haleon plc)

UCBJF's stock peer is HOCPF (HOYA Corporation)

UCBJF's stock peer is IPSEY (Ipsen S.A.)

UCBJF's stock peer is LZAGF (Lonza Group AG)

UCBJF's stock peer is LZAGY (Lonza Group AG)

UCBJF's stock peer is WUXIF (WuXi AppTec Co., Ltd.)

Healthcare Biotechnology

UCB S.A. is a prominent biopharmaceutical company dedicated to the discovery, development, and commercialization of innovative therapies for individuals affected by neurological and immunological disorders. Its extensive portfolio of marketed products includes Cimzia, indicated for various inflammatory TNF-mediated diseases such as Crohn's disease, plaque psoriasis, psoriatic arthritis, rheumatoid arthritis, ankylosing spondylitis, and axial spondyloarthritis (both radiographic and non-radiographic forms). For epilepsy management, UCB provides Vimpat, Keppra, and Briviact, alongside Nayzilam, a specialized nasal spray for acute rescue treatment of seizure clusters. Neupro is available for patients with Parkinson's disease and restless legs syndrome, while Zyrtec and Xyzal address allergy symptoms. Additionally, the company offers Evenity to treat osteoporosis in postmenopausal women, and BIMZELX, approved for conditions like psoriasis, psoriatic arthritis, axial spondyloarthritis, and hidradenitis suppurativa. Dapirolizumab pegol is also part of its offerings for systemic lupus erythematosus. In its robust development pipeline, UCB is advancing several investigational medicines, including rozanolixizumab for myasthenia gravis, immune thrombocytopenia, and chronic inflammatory demyelinating polyneuropathy; zilucoplan for myasthenia gravis and immune-mediated necrotizing myopathy; staccato alprazolam for prolonged stereotypical seizures; Bepranemab targeting Alzheimer's disease; and UCB0599 for Parkinson's disease. Beyond its core pharmaceutical activities, UCB also provides contract manufacturing services. The company has forged strategic collaboration agreements with major industry players such as Amgen, Biogen, Roche/Genentech, Novartis, Otsuka, and doc.ai. With its headquarters in Brussels, Belgium, and established in 1925, UCB maintains a significant international presence, operating across the United States, Japan, Germany, China, Belgium, and other key European markets including France, Italy, Spain, the United Kingdom, and Ireland.

80%

Dcf Rating

80%

Return On Equity

100%

Return On Assets

40%

Debt To Equity

20%

Price To Earnings

40%

Price To Book

Income Statement

Dividend Stats Yield is calculated via trailing-12-month period

Ex-Dividend	Payment Date	Dividend	Yield	Dividend Frequency
2026-05-05	2026-05-06	1.70	0.61 %	Annual
2025-04-28	2025-04-29	1.58	1.05 %	Annual
2024-04-29	2024-04-30	1.45	1.09 %	Annual
2023-05-02	2023-05-03	1.46	1.58 %	Annual
2022-05-02	2022-05-03	1.37	1.13 %	Annual
2021-05-03	2021-05-04	1.53	1.57 %	Annual
2020-05-05	2020-05-06	1.35	1.48 %	Annual
2019-04-29	2019-04-30	1.35	1.54 %	Annual
2018-04-30	2018-05-02	1.43	1.94 %	Annual
2017-05-02	2017-05-03	1.25	1.62 %	Annual
2016-05-02	2016-05-03	1.26	1.59 %	Annual
2015-05-05	2015-05-06	1.18	1.65 %	Annual
2014-05-02	2014-05-05	1.44	1.80 %	Annual
2013-05-06	2013-05-07	1.33	1.64 %	Annual
2012-05-02	2012-05-03	1.32	2.82 %	Annual
		0.98	2.04 %	Annual
		0.96	2.46 %	Annual
		0.92	3.56 %	Annual

Recent News

UCB Announces Publication of Data in Brain Communications Demonstrating Positive Impact of KYGEVVI® (doxecitine and doxribtimine) in Patients with Thymidine Kinase 2 Deficiency (TK2d)

Data indicate that KYGEVVI therapy improved survival and functional outcomes in people with TK2d.1 Additional data from the largest pool of information on TK2d illustrates the impact and burden of disease progression2 and highlights the benefits of early diagnosis.3 ATLANTA, June 17, 2026 /PRNewswire/ -- UCB, a global biopharmaceutical company, today announced the publication of two manuscripts in Brain Communications. One manuscript reports integrated safety and efficacy findings for KYGEVVI® (doxecitine and doxribtimine), the first and only approved treatment for adults and pediatric patients with early-onset thymidine kinase 2 deficiency (TK2d) with a symptom onset on or before 12 years of age, demonstrating improved survival and functional outcomes in treated patients, along with acceptable tolerability.1 A second manuscript features findings from the largest published dataset of untreated patients with TK2d, illustrating the progressive burden of disease and increased risk of early death, thus reinforcing the importance of timely diagnosis and treatment.2 "TK2d can have a devastating impact on patients and families if left untreated, which the data compiled and published in Brain Communications confirm," said Caterina Garone, Associate Professor of Medical Genetics, University of Bologna, Italy, and co-author of both studies.

2026-06-17 07:00:00

UCB Unifies Global Pharmacovigilance Operations with Veeva Safety Suite

End-to-end safety foundation to speed case processing and enable automation PLEASANTON, Calif., June 9, 2026 /PRNewswire/ -- Veeva Systems (NYSE: VEEV) today announced that UCB is unifying its global safety operations with Veeva Safety Suite to maximize operational efficiency and scale.

2026-06-09 07:03:00

UCB and Biogen Announce Publication in The Lancet of Positive Dapirolizumab Pegol (DZP) Phase 3 Study Results in Systemic Lupus Erythematosus

BRUSSELS, Belgium and CAMBRIDGE, Mass., June 01, 2026 (GLOBE NEWSWIRE) -- UCB (Euronext Brussels: UCB) and Biogen Inc. (Nasdaq: BIIB) today announced that The Lancet, a world-leading medical journal, has published the full results from the Phase 3 PHOENYCS GO clinical trial evaluating dapirolizumab pegol (DZP), an investigational, novel Fc-free CD40L inhibitor, in patients living with moderate-to-severe active systemic lupus erythematosus (SLE). The results showed statistically significant improvement in disease activity with DZP added to standard of care (SOC) versus placebo plus standard of care.1

2026-06-01 01:30:00

Disclaimers

StockQuay.com is not operated by a broker, dealer, or registered investment advisor. Under no circumstances should any information published on StockQuay.com be considered a recommendation to buy, sell, or hold any security. The content on this site and in its associated newsletters is intended solely for informational and educational purposes and does not constitute investment advice or financial recommendations.

Individuals or entities featured or referenced on StockQuay.com may engage in trading activity involving the securities mentioned in any article or report before or after such content is published. These individuals or entities are not affiliated with StockQuay.com, and their inclusion does not imply endorsement or accuracy of their views or actions.

StockQuay.com, its owners, or its affiliates shall not be held liable to any user or third party for any damages or losses arising from the use of content on this website. This includes, but is not limited to, investment losses, loss of profit, loss of data, missed opportunities, or indirect, incidental, or consequential damages.

Data is updated daily and is not guaranteed to be accurate or complete.

Past performance is not indicative of future results. Please conduct your own research or consult with a qualified financial advisor before making any investment decisions